If you have been reading about actin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
Sport in modern India is a nexus of little-known indigenous traditions and commercial sporting events with worldwide reach. Traditional sports such as kabaddi and kho-kho have experienced a resurgence, attracting large television audiences; on the other hand, kushti wrestling in rural akharas—often regarded by its practitioners as not so much a sport as a physical and moral regimen—has continued to survive away from the exposure of broadcasting. Cricket is India's most watched sport and a multi-billion dollar industry. The widespread popularity of chess among youth in southern India culminated in 18-year-old Gukesh Dommaraju of Chennai winning the undisputed World Chess Champion title in 2024. British intervention reshaped India's athletic landscape. It introduced cricket, football and field hockey and institutionalised polo—a sport whose history is a case of reverse migration from India to the West. Today, at the rural grassroots level, government initiatives like "Khelo India" have democratised athletics for traditionally overlooked youth. Rural soccer programs have employed teamwork to break down old caste barriers. State initiatives such as the Target Olympic Podium Scheme have expanded resources for female athletes; meanwhile, the prominent international victories of figures like boxer Mary Kom and badminton player P. V. Sindhu have challenged traditional gender stereotypes in sports. India has won eight men's cricket ICC tournament titles: two Cricket World Cups, three T20 World Cups, and three Champions Trophy titles.
Degenerative suspensory ligament desmitis, commonly called DSLD, also known as equine systemic proteoglycan accumulation (ESPA), is a systemic disease of the connective tissue of the horse and other equines. It is a disorder akin to Ehlers–Danlos syndrome being researched in multiple horse breeds. Originally thought to be a condition of overwork and old age, the disease is now recognized as hereditary and has been seen in horses of all ages, including foals. The latest research (2010) has led to the proposed renaming of the disease from DSLD to ESPA because of the systemic and hereditary components now being found.
Peptide-methionine (S)-S-oxide reductase (EC 1.8.4.11, MsrA, methionine sulphoxide reductase A, methionine S-oxide reductase (S-form oxidizing), methionine sulfoxide reductase A, peptide methionine sulfoxide reductase, formerly protein-methionine-S-oxide reductase) is an enzyme with systematic name peptide-L-methionine:thioredoxin-disulfide S-oxidoreductase (L-methionine (S)-S-oxide-forming). This enzyme catalyses the following chemical reaction
Unk is sometimes used instead of Xaa, but is less standard. Ter or * (from termination) is used in notation for mutations in proteins when a stop codon occurs. It corresponds to no amino acid at all. In addition, many nonstandard amino acids have a specific code. For example, several peptide drugs, such as Bortezomib and MG132, are artificially synthesized and retain their protecting groups, which have specific codes. Bortezomib is Pyz–Phe–boroLeu, and MG132 is Z–Leu–Leu–Leu–al. To aid in the analysis of protein structure, photo-reactive amino acid analogs are available. These include photoleucine (pLeu) and photomethionine (pMet).
Sources: en.wikipedia.org
Where b is binding rate, and k is processing rate. Since the dissociation rate of the substrate-SU complex to (unchanged) substrate and (unbounded) SU is assumed to be small, d θ . d t {\displaystyle {\frac {d\theta _{.}}{dt}}} and d θ S d t {\displaystyle {\frac {d\theta _{S}}{dt}}} are assumed to be zero. This system of equation suggests the free SU percentage is θ . = k b S + k {\displaystyle \theta _{.}={\frac {k}{bS+k}}} and the product of flux is J p = k S S + S / b {\displaystyle J_{p}={\frac {kS}{S+S/b}}} The first modification is an extension of the classic theory; if arrival fluxes are taken proportional to substrate concentrations, the classic theory results. This extension allows application in spatially heterogeneous environments (such as in living cells), and to treat photons and molecules in the same framework (important in photosynthesis).
Krypton-85, with a half-life 10.76 years, is formed by the fission process with a fission yield of about 0.3%. Only 20% of the fission products of mass 85 become 85Kr itself; the rest passes through a short-lived nuclear isomer and then to stable 85Rb. If irradiated reactor fuel is reprocessed, this radioactive krypton may be released into the air. This krypton release can be detected and used as a means of detecting clandestine nuclear reprocessing. Strictly speaking, the stage which is detected is the dissolution of used nuclear fuel in nitric acid, as it is at this stage that the krypton and other fission gases like the more abundant xenon are released. Despite the industrial applications of krypton-85 and the relatively high prices of both krypton and xenon, they are not currently extracted from spent fuel to any appreciable extent even though krypton and xenon both become solid at the temperature of liquid nitrogen and could thus be captured in a cold trap if the flue gas of a voloxidation process were cooled by liquid nitrogen. Increase of fission gases above a certain limit can lead to fuel pin swelling and even puncture, so that fission gas measurement after discharging the fuel from the reactor is most important to make burn-up calculations, to study the nature of fuel inside the reactor, behaviour with pin materials, for effective utilization of fuel and also reactor safety. In addition to that, they are a nuisance in a nuclear reactor due to being neutron poisons, albeit not to the same extent as isotopes of xenon, another noble gas produced by fission.
== Inventions == In 2023, she and an investigative team created a "Floor and small surface cleaner formula without water in its formulation presented in fast dissolving crystals with antibacterial effect" as well as "Compact powder Compact powder soap that dissolves quickly in the time necessary to ensure hand cleaning with moisturizing effect" those inventions were recognized by International Invention and Innovation Competition in Canada (iCAN). Her most awarded invention is the "Emulsion type cosmetic cream for face and body with moisturizing effect formulated with sinami (Oenocorpus mapora H. Karst)". This patent was created in collaboration with Dr. Luciana de la Fuente Carmelino and Mg. Juana Patricia Lozada Huancachoque, and it received the golden medals at the KIWIE Awards in 2024. Their others two inventions, that received this award, were "Formula and application method for the cleaning of cloudiness generated by weathering in glass containers" and "Toothpaste in tablet form free of water in its formulation with essential oils as antimicrobial active ingredients".
They gained promotion to the Championship following a 3–1 win over Millwall in the play-off final later that season. In September 2016, Barnsley were caught up in an ongoing scandal in English football, with assistant manager Tommy Wright alleged to have accepted "bungs" in exchange for working as an ambassador for a third-party player ownership consortium. Wright was suspended and subsequently dismissed by the club.
Lipofuscin is the name given to fine yellow-brown pigment granules composed of lipid-containing residues of lysosomal digestion. It is considered to be one of the aging or "wear-and-tear" pigments, found in the liver, kidney, heart muscle, retina, adrenals, nerve cells, and ganglion cells.
Sources: en.wikipedia.org
== Uses == Nylon was first used commercially in a nylon-bristled toothbrush in 1938, followed more famously in women's stockings or "nylons" which were shown at the 1939 New York World's Fair and first sold commercially in 1940. Its use increased dramatically during World War II, when the need for fabrics increased dramatically.
Dunkin' Donuts' "It's Worth the Trip" campaign starred sleepy-eyed "Fred the Baker" and featured the catchphrase "Time to make the donuts”. It won honors from the Television Bureau of Advertising as one of the five best television advertisements of the 1980s. Fred the Baker was played by actor Michael Vale for 16 years until his retirement in 1997. The catchphrase was used in the title of founder William Rosenberg's autobiography Time to Make the Donuts: The Founder of Dunkin' Donuts Shares an American Journey.
It is likely that cut flower production in India is similar to China based on the similar population sizes. In recent decades, with the increasing use of air freight, it has become economic for high value crops to be grown far from their point of sale; the market is usually in industrialized countries. Typical of these is the production of roses in Ecuador and carnations in Colombia, mainly for the US market, and production in Kenya and Uganda for the European market. Some countries specialize in especially high value products, such as orchids from Singapore and Thailand.
=== Commercial === Commercial availability varies by country. Approved systems in various countries, described further below, include MiniMed 670G or 780G, Tandem's Control-IQ, Omnipod 5, CamAPS FX, and Diabeloop DBLG1.
== Credits == Band members Udo Dirkschneider – lead vocals, harmony vocals (4, 9, 10), backing vocals (1, 8), finger snapping (8) Wolf Hoffmann – lead & rhythm guitars (all except 9), rhythm guitar (9), acoustic guitar (1, 10), backing vocals (1, 6, 7, 10), electric sitar (1) Jörg Fischer – rhythm guitar (all except 4, 9), lead & rhythm guitars (4, 9), 8-string bass (3), backing vocals (1, 6, 7, 10), finger snapping (8) Peter Baltes – bass, Moog Taurus (1, 5, 7, 10), 8-string bass (1, 8, 10), backing vocals (1, 6, 7, 10), harmony vocals (2, 5), acoustic bass guitar (8) Stefan Kaufmann – drums, backing vocals (1, 6, 7, 10), timpani (1, 8, 10), cymbals and gongs (1), drum effects and gang vocals (3) Production Dieter Dierks – producer, arrangements Gerd Rautenbach – engineer Mike Kashnitz, Peter Brandt – assistant engineers Bob Ludwig – mastering at Masterdisk, New York Gaby "Deaffy" Hauke – management, cover concept Dirksen & Sohn Modellwerkstâtten, Stahl, Werbefotografie – cover art
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.